Hints and tips:
...Takeda has adopted a cautious approach to investing in vaccines and has a limited pipeline of opportunities....
...In a joint statement, Moderna and its Japanese distribution partner Takeda Pharmaceutical said they took the deaths seriously....
...Shareholders were rightly worried by Takeda’s $62bn acquisition of London-listed rival Shire two years ago. The Japanese pharmaceuticals group is still weighed down by the resulting debt....
...“The bulk of the vaccines I think will come from other sources” such as Oxford/AstraZeneca and Russia’s Sputnik V, said one Pakistani official....
...Other vaccines being deployed include BioNTech/Pfizer, Oxford/AstraZeneca and the Russian Sputnik V jab....
...The Czech Republic, which is facing a surge in infections, could start using the Sputnik V vaccine, Prime Minister Andrej Babis said on Sunday....
...In Hungary, Sinopharm’s vaccines were bought for $36 per dose, more than three times the price of Russia’s Sputnik V. Senegal paid $19 per dose for Sinopharm jabs....
...This month, the Russian Sputnik V was also offered. Abu Dhabi has deepened its relations with China during the pandemic, sharing information on the virus and collaborating on vaccines and testing....
...Of others joined in the chase, including Mitsubishi Tanabe Pharma, I’rom Group and Takeda Pharmaceutical, the last offers the best chances....
...Christophe Weber, chief executive of Takeda, the Japanese pharmaceuticals company, called for fewer barriers to the collection and use of so-called convalescent plasma which is pooled from patients who have...
...Takeda said it was due to pay $156.7m in other costs and expenses....
...Although 2019 did not have a mega-deal to match Takeda Pharmaceutical’s $62bn purchase of Shire, which was announced in 2018, there was a steady increase in both the number and size of deals as more sectors...
...Idexx said in October that the animal health market had experienced a “V-shaped recovery”....
...Takeda completed the £46bn acquisition of Irish drugmaker Shire in January, part of a flurry of multibillion-dollar pharmaceutical deals as traditional drugmakers seek to buy other companies to combat expiring...
...Takeda Pharmaceutical has completed its £46bn acquisition of Shire, catapulting the 237-year-old Japanese group into one of the world’s largest drugmakers with combined revenues of $31bn ....
...Takeda will consider selling businesses from its Nycomed acquisition in 2011, as Japan’s largest pharmaceutical group seeks to divest $10bn of assets after completing a £46bn deal to buy Shire....
...Takeda says it took account of competition in its valuation of the Irish company....
...Advisors to institutional investors have given the all clear for what would be corporate Japan’s largest ever overseas takeover, the £46bn ($59bn) purchase of the UK’s Shire by Takeda Pharmaceutical....
...Some, such as Christophe Weber at Takeda Pharmaceutical and Sarah Casanova at McDonald’s Japan, are regarded as successful....
...The upgrade came as Japan’s largest drugmaker seeks to close its £46bn takeover of Irish drugmaker Shire in a bid to strengthen its pipeline and catapult the company into the ranks of the world’s biggest pharmaceutical...
...Brussels has approved Takeda Pharmaceutical’s £46bn takeover of Shire with conditions, an important milestone for Japan’s biggest overseas takeover....
...Takeda Pharmaceutical has won shareholder approval to finance its £46bn purchase of Shire, paving the way for Japan’s largest corporate takeover and the creation of a global drugmaker with combined revenues...
...The Japanese pharmaceuticals group has brought forward a meeting to approve financing. A stiff censure vote is merited, all the same....
...into the ranks of the world’s biggest pharmaceutical companies....
International Edition